์นด๋ฅด๋ฒ ๋๋กค
์นด๋ฅด๋ฒ ๋๋กค์ **์ํ-1 ์๋๋ ๋ ๋ฆฐ ์ฐจ๋จ** ํน์ฑ์ ๊ฐ์ง ๋ ํนํ 3์ธ๋ **๋น์ ํ์ ๋ฒ ํ ์ฐจ๋จ์ **์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก **๊ฐ ํ์ฅ์ฑ ์ฌ๊ทผ๋ณ์ฆ(DCM)** ๋ฐ ๋ง์ฑ ์ฌ๋ถ์ ์ ๋ณด์กฐ ์น๋ฃ์ ๋ก ์ฐ๊ตฌ๋๊ณ ์์ต๋๋ค. * **์ด์ค ์์ฉ:** ๊ธฐ์กด์ ๋ฒ ํ ์ฐจ๋จ์ (์: ์ํ ๋๋กค)์ ๋ฌ๋ฆฌ ์นด๋ฅด๋ฒ ๋๋กค์ ์ถ๊ฐ์ ์ธ ํ๊ด ํ์ฅ ํจ๊ณผ๋ฅผ ์ ๊ณตํ์ฌ ์ฌ์ฅ์ ํ๋ถํ๋ฅผ ๊ฐ์์ํต๋๋ค. * **๋ ผ๋์ด ๋๋ ์ฌ์ฉ:** ์์ ์ฌ์ฅํ์์์ ์ฌ์ฉ์ ์ฌ์ ํ ๋ ผ๋์ ์ฌ์ง๊ฐ ์์ต๋๋ค. ์ธ์ฒด ์ฌ๋ถ์ ์์๋ ์ฌ๋ง๋ฅ ๊ฐ์ ํจ๊ณผ๊ฐ ์ ์ฆ๋์์ผ๋, ๊ฐ๋ฅผ ๋์์ผ๋ก ํ ์ฐ๊ตฌ์์๋ ํ์ค ์ฉ๋ ํฌ์ฌ ์ ์ ๊ฒฝํธ๋ฅด๋ชฌ ํ์ฑํ๋ ์ฌ์ค ์ฌํ์ฑ ๊ฐ์ ์ ๋ํ ํจ๋ฅ ๊ฒฐ๊ณผ๊ฐ ์๊ฐ๋ฆฝ๋๋ค. * **์์์ ํต์ฌ:** ์นด๋ฅด๋ฒ ๋๋กค์ ๊ฐ๋ ฅํ ์์ฑ ๋ณ๋ ฅ ์์ฉ์ ํฉ๋๋ค. ์งํ์ฑ ๋๋ ์ฆ์์ด ์ฌํ ์ฌ๋ถ์ ํ์์์ ๊ธ์ฑ ๋น๋์์ฑ์ ์ ๋ฐํ ์ ์์ต๋๋ค. ๋งค์ฐ ์ฃผ์ ๊น๊ณ ์ฒ์ฒํ ์ฉ๋์ ์ฆ๋ํด์ผ ํ๋ฉฐ, ์ฆ์์ด ๊ฒฝ๋ฏธํ ํ์์์ ์์ํ๋ ๊ฒ์ด ๊ฐ์ฅ ์ข์ต๋๋ค.
์์ฉ ๊ธฐ์ : Carvedilol exerts its cardiovascular effects through multiple mechanisms: * **Non-selective Beta-Adrenergic Blockade (ฮฒ1 and ฮฒ2):** Heart failure leads to chronic sympathetic nervous system (SNS) activation โ tachycardia, renin-angiotensin-aldosterone system (RAAS) activation, beta-receptor downregulation, and myocyte necrosis. Carvedilol blocks these receptors โ **reverses/diminishes SNS toxicity**, reduces heart rate, and decreases myocardial oxygen demand. * **Selective Alpha-1 Adrenergic Blockade:** Blocks peripheral ฮฑ1-receptors โ **vasodilation** โ reduces systemic vascular resistance and cardiac afterload. * **Antioxidant Properties:** Carvedilol and its metabolites act as potent scavengers of reactive oxygen species (ROS) and inhibit lipid peroxidation, protecting the myocardium from oxidative stress. * **Antidysrhythmic Effects:** Secondary to its beta-blocking and membrane-stabilizing properties.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Heart failure (adjunctive therapy) ยท ยผ-ยฝ of a 3.125 mg tablet PO twice daily ยท PO ยท twice daily ยท Usual starting dose. Start at the low end of the dosing range and gradually titrate upward carefully watching to avoid negative inotropic effects.
- Early/mild heart failure or later stages of CHF ยท 0.2 mg/kg PO twice daily initially with slow titration upwards towards a dose of 0.8 mg/kg twice daily ยท PO ยท twice daily ยท Beta blockers are best employed in dogs that are minimally symptomatic. Many dogs with CHF will not tolerate this upward titration.
- Heart failure (target plasma concentration) ยท 0.5 mg/kg PO twice daily ยท PO ยท twice daily ยท Should result in beta-blockade, but maximum beta-blockade may require doses of >0.7-0.9 mg/kg. Because of bioavailability variations, plasma monitoring, clinical trials and uptitration protocols may be beneficial.
- Dilated cardiomyopathy ยท 0.3 mg/kg PO q12h ยท PO ยท q12h ยท 3 months ยท Did not produce any significant improvements in neurohormonal activation, heart size, or owner-perceived quality of life. Doses >0.3 mg/kg q12h are likely to be required to effect changes in ventricular remodeling and function.
- Chronic heart failure / Dilated Cardiomyopathy (DCM) ยท Start at 0.05-0.1 mg/kg, gradually increase at 2-week intervals to target dose of 0.3-0.4 mg/kg ยท PO ยท q12h ยท Long-term ยท Increase dose only if tolerated.
- ACVIM stage B2 degenerative mitral valve disease ยท 0.3 mg/kg, increased at intervals up to 1.1 mg/kg ยท PO ยท q12h ยท Long-term ยท For cardiac remodelling with no signs of cardiac failure.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Class IV decompensated heart failure
- Bronchial asthma
- 2nd or 3rd degree AV block
- Sick sinus syndrome (unless artificially paced)
- Severe bradycardia
- Cardiogenic shock
- Hypersensitivity to the drug
์ด์๋ฐ์
- Inappetence
- Lassitude (lethargy/fatigue)
- Hypotension
- Decompensation of heart failure (if titrated too rapidly)
- Bronchospasm (reported in humans)
- Mild hepatocellular injury (rare)
์ฝ๋ฌผ ์ํธ์์ฉ
- Beta-Blockers (other) ยท Use with carvedilol may cause additive effects
- Calcium Channel Blockers (e.g., diltiazem, verapamil) ยท May rarely cause hemodynamic compromise
- Cimetidine ยท May decrease metabolism and increase AUC of carvedilol
- Clonidine ยท Carvedilol may potentiate the cardiovascular effects of clonidine
- Cyclosporine ยท Carvedilol may increase cyclosporine levels
- Digoxin ยท Can increase digoxin plasma concentrations by approximately 15% ยท major
- Fluoxetine, Paroxetine, Quinidine ยท May increase R(+)carvedilol concentrations and increase alpha-1 blocking effects (vasodilation)
- Insulin / Oral Antidiabetic Agents ยท Carvedilol may enhance the blood glucose lowering effects of insulin or other antidiabetic agents
- Rifampin ยท Can decrease carvedilol plasma concentrations by as much as 70% ยท moderate
- Reserpine ยท Can cause increased bradycardia and hypotension in patients taking carvedilol
- Anaesthetic agents ยท Enhanced hypotensive effect and myocardial depression ยท major
- Phenothiazines ยท Enhanced hypotensive effect ยท moderate
๋ชจ๋ํฐ๋ง
- Clinical efficacy (improvement in heart failure signs)
- Adverse effects (lethargy, inappetence, hypotension, worsening heart failure)
- Plasma drug levels (Target: 50-100 nanograms/mL)
๊ณผ์ฉ๋
The acute oral LD50 in healthy rats and mice is greater than 8 grams/kg. **Clinical Signs of Overdose:** * Severe hypotension * Cardiac insufficiency * Bradycardia * Cardiogenic shock * Death due to cardiac arrest **Treatment:** * Gut emptying protocols should be considered if ingestion was recent. * **Bradycardia:** Treat with atropine. * **Cardiovascular Support:** Support function with glucagon and sympathomimetics (e.g., dobutamine, epinephrine). * Contact an animal poison control center for specific information.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.